Statins: Cardiovascular risk reduction in percutaneous coronary interventionbasic and clinical evidence of hyperacute use of statins

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Morales Villegas, Enrique C ^a   Di Sciascio, Germano ^b,c   Briguori, Carlo ^d  

^a Centro de Investigación Cardiometabólica CIC   (Mexico)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Clinica Mediterranea   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ATORVASTATIN; BIOLOGICAL MARKER; CHOLESTEROL; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; ROSUVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL CYCLE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HEART MUSCLE ISCHEMIA; HUMAN; LOW DRUG DOSE; MUSCLE CELL; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; TREATMENT RESPONSE;

EID: 84857956249     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/904742     Document Type: Review

References (70)

1. Endo A., The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research 1992 33 11 1569 1582 2-s2.0-0026448725
2. Brown M. S., Goldstein J. L., A tribute to Akira Endo, discoverer of a Penicillin for the cholesterol. Atherosclerosis Supplements 2004 5 13 16
3. Brown M. S., Goldstein J. L., A receptor-mediated pathway for cholesterol homeostasis. Science 1986 232 4746 34 47 (Pubitemid 16037973)
4. Goldstein J. L., Brown M. S., Regulation of the mevalonate pathway. Nature 1990 343 6257 425 430 2-s2.0-0025120211 10.1038/343425a0 (Pubitemid 20065229)
5. Goldstein J. L., Brown M. S., The LDL receptor. History of discovery. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 4 431 438 2-s2.0-63449102513 10.1161/ATVBAHA.108.179564
6. Goldstein J. L., Brown M. S., Hidrophobic Handoff Mechanism 2010 Chicago, Ill, USA American Heart Association Meeting Nobel Laureate Lecture
7. Cariou B., Ouguerram K., Zaïr Y., Guerois R., Langhi C., Kourimate S., Benoit I., Le May C., Gayet C., Belabbas K., Dufernez F., Chétiveaux M., Tarugi P., Krempf M., Benlian P., Costet P., PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 12 2191 2197 2-s2.0-73849114174 10.1161/ATVBAHA.109.194191
8. Ginsberg H. N., Le N. A., Short M. P., Ramakrishnan R., Desnick R. J., Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. Journal of Clinical Investigation 1987 80 6 1692 1697 2-s2.0-0023481283 (Pubitemid 18007143)
9. Arad Y., Ramakrishnan R., Ginsberg H. N., Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. Journal of Lipid Research 1990 31 4 567 582 2-s2.0-0025345666 (Pubitemid 20167624)
10. Istvan E. S., Deisenhofer J., Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001 292 5519 1160 1164 2-s2.0-0035843962 10.1126/science.1059344 (Pubitemid 32440937)
11. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., Warwick M., Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. American Journal of Cardiology 2001 87 supplement 28B 32B 2-s2.0-0035825928 (Pubitemid 32274242)
12. Holdgate G. A., Ward W. H. J., McTaggart F., Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochemical Society Transactions 2003 31 3 528 531 2-s2.0-0037527704 10.1042/BST0310528 (Pubitemid 36750725)
13. Jones P. H., Davidson M. H., Stein E. A., Bays H. E., McKenney J. M., Miller E., Cain V. A., Blasetto J. W., Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). American Journal of Cardiology 2003 92 2 152 160 2-s2.0-0038645309 10.1016/S0002-9149(03)00530-7 (Pubitemid 36835963)
14. McKenney J. M., Jones P. H., Adamczyk M. A., Cain V. A., Bryzinski B. S., Blasetto J. W., Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Current Medical Research and Opinion 2003 19 8 689 698 2-s2.0-0345708294 10.1185/030079903125002405 (Pubitemid 37466137)
15. Nicholls S. J., Brandrup-Wognsen G., Palmer M., Barter P. J., Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatina versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). American Journal of Cardiology 2010 105 1 69 76 2-s2.0-72049130254 10.1016/j.amjcard.2009.08.651
16. Casey P. J., Protein lipidation in cell signaling. Science 1995 268 5208 221 225 2-s2.0-0028935780
17. Zhang F. L., Casey P. J., Protein prenylation: molecular mechanisms and functional consequences. Annual Review of Biochemistry 1996 65 241 269 2-s2.0-0029898894 (Pubitemid 26250610)
18. Liao J. K., Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation 2002 110 3 285 288 2-s2.0-0036322869 10.1172/JCI200216421 (Pubitemid 34847957)
19. Dichtl W., Dulak J., Frick M., Alber H. F., Schwarzacher S. P., Ares M. P. S., Nilsson J., Pachinger O., Weidinger F., HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 1 58 63 2-s2.0-0037233913 10.1161/01.ATV.0000043456.48735.20 (Pubitemid 36091626)
20. McFarlane S. I., Muniyappa R., Francisco R., Sowers J. R., Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. Journal of Clinical Endocrinology and Metabolism 2002 87 4 1451 1458 2-s2.0-0036280932 10.1210/jc.87.4.1451 (Pubitemid 34615220)
21. Liao J. K., Laufs U., Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005 45 89 118 2-s2.0-10644286120 10.1146/annurev.pharmtox.45.120403.095748 (Pubitemid 40261799)
22. Sen-Banerjee S., Mir S., Lin Z., Hamik A., Atkins G. B., Das H., Banerjee P., Kumar A., Jain M. K., Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005 112 5 720 726 2-s2.0-23244457776 10.1161/CIRCULATIONAHA.104.525774 (Pubitemid 41099052)
23. Kircher M. F., Grimm J., Swirski F. K., Libby P., Gerszten R. E., Allport J. R., Weissleder R., Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation 2008 117 3 388 395 2-s2.0-38349114229 10.1161/CIRCULATIONAHA.107.719765
24. Rudd J. H. F., Hyafil F., Fayad Z. A., Inflammation imaging in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 7 1009 1016 2-s2.0-67650315442 10.1161/ATVBAHA.108.165563
25. Bell R. M., Yellon D. M., Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. Journal of the American College of Cardiology 2003 41 3 508 515 2-s2.0-0037419766 10.1016/S0735-1097(02)02816-4 (Pubitemid 36164511)
26. Prasad A., prasad.abhiram@mayo.edu Stone G. W., Holmes D. R., Gersh B., Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation 2009 120 21 2105 2112 10.1161/CIRCULATIONAHA.108.814640
27. Ludman A., Venugopal V., Yellon D. M., Hausenloy D. J., Statins and cardioprotectionmore than just lipid lowering? Pharmacology and Therapeutics 2009 122 1 30 43 2-s2.0-63149166444 10.1016/j.pharmthera.2009.01.002
28. Young L. H., lawrence.young@yale.edu AMP-activated protein kinase conducts the ischemic stress response orchestra. Circulation 2008 117 6 832 840 10.1161/CIRCULATIONAHA.107.713115 (Pubitemid 351640685)
29. Ellis S. G., Anwaruddin S., Recapturing the magic. Revisiting the pleiotropic effects of statins in percutaneous coronary revascularization. Journal of the American College of Cardiology 2009 54 6 566 568 2-s2.0-67651024085 10.1016/j.jacc.2009.04.070
30. Hausenloy D. J., Yellon D. M., Cell membrane repair as a mechanism for ischemic preconditioning? Circulation 2010 121 23 2547 2549 2-s2.0-77953812184 10.1161/CIRCULATIONAHA.110.958462
31. Mensah K., Mocanu M. M., Yellon D. M., Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? Journal of the American College of Cardiology 2005 45 8 1287 1291 2-s2.0-17144405293 10.1016/j.jacc.2005.01.021 (Pubitemid 40523151)
32. Chang S. M., Yazbek N., Lakkis N. M., nlakkis@faculty.bcm.tmc.edu Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheterization and Cardiovascular Interventions 2004 62 2 193 197 10.1002/ccd.20078 (Pubitemid 38788696)
33. Nusca A., Melfi R., Patti G., Di Sciascio G., Statin loading for acute coronary syndromes. Current Opinion in Cardiology 2010 25 4 373 378 2-s2.0-77953807695 10.1097/HCO.0b013e32833987ca
34. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., Di Sciascio G., Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004 110 6 674 678 2-s2.0-4043133008 10.1161/01.CIR.0000137828.06205.87 (Pubitemid 39056265)
35. Patti G., Chello M., Pasceri V., Colonna D., Nusca A., Miglionico M., D'Ambrosio A., Covino E., Di Sciascio G., g.disciascio@unicampus.it Protection from procedural Myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention. Results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules). Journal of the American College of Cardiology 2006 48 8 1560 1566 10.1016/j.jacc.2006.06.061 (Pubitemid 44528186)
36. Briguori C., Colombo A., Airoldi F., Violante A., Focaccio A., Balestrieri P., Elia P. P., Golia B., Lepore S., Riviezzo G., Scarpato P., Librera M., Bonizzoni E., Ricciardelli B., Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. European Heart Journal 2004 25 20 1822 1828 2-s2.0-4944219936 10.1016/j.ehj.2004.07.017 (Pubitemid 39330233)
37. Briguori C., Visconti G., Focaccio A., Golia B., Chieffo A., Castelli A., Mussardo M., Montorfano M., Ricciardelli B., Colombo A., Novel Aproaches for Preventing or Limiting Events (Naples) II trial. Impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. Journal of the American College of Cardiology 2009 54 23 2157 2163 2-s2.0-70449707877 10.1016/j.jacc.2009.07.005
38. Patti G., Pasceri V., Colonna G., Miglionico M., Fischetti D., Sardella G., Montinaro A., Di Sciascio G., Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Results of the ARMYDA-RECAPTURE randomized trial. Journal of the American College of Cardiology 2007 49 12 1272 1278 2-s2.0-33947517527 10.1016/j.jacc.2007.02.025 (Pubitemid 46467240)
39. Di Sciascio G., Patti G., Pasceri V., Gaspardone A., Colonna G., Montinaro A., Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention. Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. Journal of the American College of Cardiology 2009 54 6 558 565 2-s2.0-67651033611 10.1016/j.jacc.2009.05.028
40. Di Sciascio G., Personal communication.
41. Yun K. H., Jeong M. H., Oh S. K., Rhee S. J., Park E. M., Lee E. M., Yoo N. J., Kim N. H., Ahn Y. K., Jeong J. W., The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. International Journal of Cardiology 2009 137 3 246 251 2-s2.0-70749159902 10.1016/j.ijcard.2008.06.055
42. Kim J. S., Kim J., Choi D., Lee C. J., Lee S. H., Ko Y. G., Hong M. K., Kim B. K., Oh S. J., Jeon D. W., Yang J. Y., Cho J. R., Lee N. H., Cho Y. H., Cho D. K., Jang Y., Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. American College of Cardiology Interview 2010 3 3 332 339 2-s2.0-77949337131 10.1016/j.jcin.2009.11.021
43. Thygesen K., Alpert J. S., White H. D., On behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redifinition of Myocardial Infarction. Universal definition of myocardial infarction. European Heart Journal 2001 28 2535 2538
44. Heusch G., gerd.heusch@uk-essen.de Kleinbongard P., Böse D., Levkau B., Haude M., Schulz R., Erbel R., Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009 120 18 1822 1836 10.1161/CIRCULATIONAHA.109.888784
45. Prasad A., Singh M., Lerman A., Lennon R. J., Holmes D. R., Rihal C. S., Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. Journal of the American College of Cardiology 2006 48 9 1765 1770 2-s2.0-33750447973 10.1016/j.jacc.2006.04.102 (Pubitemid 44648624)
46. Nissen S. E., Tuzcu E. M., Schoenhagen P., Brown B. G., Ganz P., Vogel R. A., Crowe T., Howard G., Cooper C. J., Brodie B., Grines C. L., DeMaria A. N., Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. Journal of the American Medical Association 2004 291 9 1071 1080 2-s2.0-10744225301 10.1001/jama.291.9.1071 (Pubitemid 38541684)
47. Nissen S. E., nissens@ccf.org Tuzcu E. M., Schoenhagen P., Crowe T., Sasiela W. J., Tsai J., Orazem J., Magorien R. D., O'Shaughnessy C., Ganz P., Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. The New England Journal of Medicine 2005 352 1 29 38 10.1056/NEJMoa042000 (Pubitemid 40075678)
48. Nissen S. E., Nicholls S. J., Sipahi I., Libby P., Raichlen J. S., Ballantyne C. M., Davignon J., Erbel R., Fruchart J. C., Tardif J. C., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., Tuzcu E. M., Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Journal of the American Medical Association 2006 295 13 1556 1565 2-s2.0-33645524176 10.1001/jama.295.13.jpc60002
49. Rodés-Cabau J., Tardif J. C., Cossette M., Bertrand O. F., Ibrahim R., Larose E., Grégoire J., L'Allier P. L., Guertin M. C., Acute effects of statin therapy on coronary atherosclerosis following acute coronary syndromes. American Journal of Cardiology 2009 104 6 750 757 2-s2.0-69449104984 10.1016/j.amjcard.2009.05.009
50. Cholesterol Treatment Trialist (CTT) Collaborators, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomized trials of statins. The Lancet 2005 366 1267 1278
51. Sever P. S., Dahlöf B., Poulter N. R., n.poulter@imperial.ac.uk Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., Östergren J., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet 2003 361 9364 1149 1158 10.1016/S0140-6736(03)12948-0 (Pubitemid 36398384)
52. Colhoun H. M., helen.colhoun@ucd.ie Betteridge D. J., Durrington P. N., Hitman G. A., Neil H. A.W., Livingstone S. J., Thomason M. J., Mackness M. I., Charlton-Menys V., Fuller J. H., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet 2004 364 9435 685 696 10.1016/S0140-6736(04)16895-5 (Pubitemid 39140624)
53. Ridker P. M., pridker@partners.org Danielson E., Fonseca F. A.H., Genest J., Gotto Jr. A. M., Kastelein J. J.P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 359 21 2195 2207 10.1056/NEJMoa0807646
54. Ridker P. M., pridker@partners.org Danielson E., Fonseca F. A., Genest J., Gotto Jr. A. M., Kastelein J. J., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 2009 373 9670 1175 1182 10.1016/S0140-6736(09)60447-5
55. LaRosa J. C., Grundy S. M., Waters D. D., Shear C., Barter P., Fruchart J. C., Gotto A. M., Greten H., Kastelein J. J. P., Shepherd J., Wenger N. K., Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine 2005 352 14 1425 1435 2-s2.0-15944410609 10.1056/NEJMoa050461 (Pubitemid 40471450)
56. La Rosa J. C., Grundy S. M., Kastelein J. J., Kostis J. B., Greten H., Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin induced very low density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets (TNT) Study. American Journal of Cardiology 2007 100 747 752 (Pubitemid 47271930)
57. LaRosa J. C., Deedwania P. C., Shepherd J., Wenger N. K., Greten H., DeMicco D. A., Breazna A., Comparison of 80 mg versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the TNT trial). American Journal of Cardiology 2010 105 3 283 287 2-s2.0-74049109446 10.1016/j.amjcard.2009.09.025
58. Schwartz G. G., Olsson A. G., Ezekowitz M. D., Ganz P., Oliver M. F., Waters D., Zeiher A., Chaitman B. R., Leslie S., Stern T., Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: a randomized controlled trial. Journal of the American Medical Association 2001 285 13 1711 1718 2-s2.0-0035804846 (Pubitemid 32259905)
59. Cannon C. P., Braunwald E., McCabe C. H., Rader D. J., Rouleau J. L., Belder R., Joyal S. V., Hill K. A., Pfeffer M. A., Skene A. M., Intensive versus moderate lipid lowering with statins after acute coronary syndrome. The New England Journal of Medicine 2004 350 15 1495 1504 2-s2.0-11144355354 10.1056/NEJMoa040583 (Pubitemid 38477774)
60. Ridker P. M., pridker@partners.org Cannon C. P., Morrow D., Rifai N., Rose L. M., McCabe C. H., Pfeffer M. A., Braunwald E., C-reactive protein levels and outcomes after statin therapy. The New England Journal of Medicine 2005 352 1 20 28 10.1056/NEJMoa042378 (Pubitemid 40075677)
61. Ray K. K., Morrow D. A., Sabatine M. S., Shui A., Rifai N., Cannon C. P., Braunwald E., Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007 115 24 3071 3078 2-s2.0-34250785071 10.1161/CIRCULATIONAHA.106.666511 (Pubitemid 46956496)
62. Fuster V., In the AHA Guidelines and Scientific Statements Handbook 2009 chapter 2
63. Murphy S. A., Cannon C. P., Wiviott S. D., McCabe C. H., Braunwald E., Reduction in recurrent cardiovascular events wit intensive-lowering statin therapy compared with moderate-lipid lowering statin therapy after acute coronary syndromes from the PROVE-IT. TIMI 22 trial. Journal of the American College of Cardiology 2009 54 25 2358 2362 2-s2.0-71649112327 10.1016/j.jacc.2009.10.005
64. Amarenco P., Bogousslavsky J., Callahan III A., Goldstein L. B., Hennerici M., Rudolph A. E., Sillesen H., Simunovic L., Szarek M., Welch K. M.A., michael.welch@rosalindfranklin.edu Zivin J. A., High-dose atorvastatin after stroke or transient ischemic attack. The New England Journal of Medicine 2006 355 6 549 559 10.1056/NEJMoa061894 (Pubitemid 44202151)
65. Antonini-Canterin F., Moura L. M., Enache R., Leiballi E., Pavan D., Piazza R., Popescu B. A., Ginghin C., Nicolosi G. L., Rajamannan N. M., Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease. Circulation 2010 121 19 2130 2136 2-s2.0-77953125275 10.1161/CIRCULATIONAHA.109.891598
66. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A. M., Dimmeler S., Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001 103 24 2885 2890 2-s2.0-0035912855 (Pubitemid 32578123)
67. Landmesser U., Engberding N., Bahlmann F. H., Schaefer A., Wiencke A., Heineke A., Spiekermann S., Hilfiker-Kleiner D., Templin C., Kotlarz D., Mueller M., Fuchs M., Hornig B., Haller H., Drexler H., Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004 110 14 1933 1939 2-s2.0-20844431696 10.1161/01.CIR.0000143232.67642.7A (Pubitemid 39331904)
68. Dimmeler S., dimmeler@em.uni-frankfurt.de Regulation of bone marrow-derived vascular progenitor cell mobilization and maintenance. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 6 1088 1093 10.1161/ATVBAHA.109.191668
69. Akram O. N., Bernier A., Petrides F., Wong G., Lambert G., Beyond LDL cholesterol, a new role for pcsk9. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 7 1279 1281 2-s2.0-77953947567 10.1161/ATVBAHA.110.209007
70. Morales-Villegas E., Atlas de Riesgo Cardio Metabólico Total 2009 1st Aguascalientes, Mexico Atheros